Richard Benjamin, MD

Cerus Corporation, Concord, CA, USA
Concord, California, United States

Presentation(s):

• OA4-AM24-MN-23 - Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in the ReCePI Phase III Clinical Trial

  Monday, October 21, 2024
  2:00 PM - 3:00 PM  

  Disclosure information not submitted.